摘要
目的观察补肺汤联合布地格福吸入气雾剂治疗稳定期慢性阻塞性肺疾病肺气虚证临床效果及安全性。方法合计纳入98例稳定期慢性阻塞性肺疾病肺气虚证患者(2021年1月—2024年3月收集)以随机数字表法进行分组,将患者平均分为布地格福组及联合汤剂组,各49例,布地格福组患者均采取布地格福吸入气雾剂治疗,联合汤剂组患者在采取布地格福吸入气雾剂治疗基础上联合补肺汤治疗,比较各组数据:临床疗效及治疗前后咳喘无力、畏风、咳痰、自汗、痰清稀等中医证候积分变化、肺功能以及炎症因子相关指标变化、T淋巴细胞变化、圣乔治呼吸调查问卷(SGRQ)变化、观察不良反应。结果联合汤剂组患者治疗总有效率比布地格福组更高(P<0.05);治疗前两组患者咳喘无力、畏风、咳痰、自汗、痰清稀等中医证候积分、第一秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、第1秒用力呼气容积占肺活量比值(FEV_(1)/FVC)等肺功能指标、白介素-4(IL-4)及白介素-8(IL-8)以及肿瘤坏死因子-α(TNF-α)等炎症因子、CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)等T淋巴细胞指标、SGRQ评分比较,差异无统计学意义(P>0.05),治疗后两组患者咳喘无力、畏风、咳痰、自汗、痰清稀等中医证候积分、肺功能指标(FEV_(1)、FVC、FEV_(1)/FVC)、炎症因子水平(IL-4、IL-8及TNF-α)、CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)等T淋巴细胞指标、SGRQ评分均明显改善,联合汤剂组患者治疗后咳喘无力、畏风、咳痰、自汗、痰清稀等中医证候积分、肺功能指标(FEV_(1)、FVC、FEV_(1)/FVC)、炎症因子水平(IL-4、IL-8及TNF-α)、CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)等T淋巴细胞指标、SGRQ评分均优于布地格福组,P<0.05;布地格福组出现1例恶心,联合汤剂组未见治疗不良反应,差异无统计学意义(P>0.05)。结论补肺汤联合布地格福吸入气雾剂治疗稳定期慢性阻塞性肺疾病肺气虚证临床效果良好,患者炎症得以控制,临床症状及肺功能改善,耐力及生活质量、免疫功能提升,未见不良反应,治疗较为安全可靠。
Objective To observe the clinical effect and safety of Bufei Decoction(补肺汤)combined with Budigefo inhalation aerosol in the treatment of lung Qi deficiency syndrome in stable chronic obstructive pulmonary disease.Methods A total of 98 patients with lung Qi deficiency syndrome of stable chronic obstructive pulmonary disease admitted from January 2021 to March 2024 were divided by random number table method,and the patients were evenly divided into Budigofort group and combined decoction group,with 49 cases in each group.All patients in the Budigofort group were treated with Budigofort inhalation aerosol.Those in the combined decoction group were treated with Budegforfo inhalation aerosol combined with Bufei decoction,and the data of each group was compared,including the clinical efficacy,the changes in TCM syndrome scores such as cough and asthma,wind resistance,phlegm cough,spontaneous sweating,phlegm clearing and other related indicators,the changes in lung function,inflammatory factors,T lymphocytes,Saint George Respiratory Questionnaire(SGRQ)before and after treatment.Results The total effective rate of the combined decoction group was higher than that of Budegforo group(P<0.05).Before treatment,the comparison of lung function indicators such as forced expiratory volume(FEV_(1)),forced vital capacity(FVC)and the ratio of FEV_(1)/FVC,inflammatory factors such as interleukin-4(IL-4)and interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),T lymphocyte indicators such as CD_(4)^(+),CD_(8)^(+)and CD_(4)^(+)/CD_(8)^(+)and SGRQ scores were not significant(P>0.05).After treatment,the traditional Chinese medicine syndrome scores of cough and asthma,wind fear,sputum cough,spontaneous sweating and clear phlegm,lung function indexes(FEV_(1),FVC,FEV_(1)/FVC),inflammatory factor levels(IL-4,IL-8 and TNF-α),CD_(4)^(+),CD_(8)^(+)and CD_(4)^(+)/CD_(8)^(+)and SGRQ score were significantly improved.And those in the combined group were better than those of the Budigerfo group(P<0.05).There was 1 case of nausea in the Budegforo group,and no adverse reaction in the combined decoction group(P>0.05).Conclusion The clinical effect of Bufei Decoction combined with Budegforo inhalation aerosol in the treatment of lung Qi deficiency syndrome of stable chronic obstructive pulmonary disease is good.The inflammation is controlled,the clinical symptoms and lung function are improved,the endurance,quality of life and immune function are enhanced,and no adverse reactions are observed.The treatment is relatively safe and reliable.
作者
王保芹
杨敏
华文山
刘宗伟
石岫岩
WANG Baoqin;YANG Min;HUA Wenshan;LIU Zongwei;SHI Xiuyan(Lianyungang Affiliated Hospital/Lianyungang Hospital of Traditional Chinese Medicine,Nanjing University of Chinese Medicine,Lianyungang 222004,Jiangsu,China)
出处
《辽宁中医杂志》
北大核心
2026年第2期103-107,共5页
Liaoning Journal of Traditional Chinese Medicine
基金
江苏省中医药科技发展计划面上项目(MS2023121)
连云港市老龄健康科研项目(L202214)
第二批连云港市名老中医药专家传承工作室建设项目(石岫岩)。
关键词
慢性阻塞性肺疾病
肺气虚证
布地格福吸入气雾剂
补肺汤
肺功能
免疫功能
不良反应
stable chronic obstructive pulmonary disease
lung Qi deficiency syndrome
Budigford inhalation aerosol
Bufei Decoction(补肺汤)
lung function
immune function
adverse reaction
